Advertisement
U.S. markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.43-0.04 (-0.23%)
At close: 04:00PM EST
16.75 -0.68 (-3.90%)
After hours: 07:08PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close17.47
Open17.26
Bid16.73 x 800
Ask17.40 x 1200
Day's Range16.95 - 18.33
52 Week Range3.21 - 18.33
Volume11,217,677
Avg. Volume10,148,236
Market Cap4.862B
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateFeb 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iovance Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/21/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GuruFocus.com

    Iovance Biotherapeutics Inc (IOVA) Reports Q4 and Full Year 2023 Financial Results

    Net Loss: Increased to $116.4 million in Q4 and $444.0 million for the full year, reflecting investment in commercial and development activities. Research and Development: R&D expenses rose to $87.5 million in Q4, driven by manufacturing and clinical trial costs. Selling, General and Administrative Expenses: Increased to $29.9 million in Q4, supporting business growth and Proleukin integration.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

    Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Canada Amtagvi Patients Identified at Nearly All of the 30 Authorized Treatment Centers (ATCs), with Approximately 50 ATCs Anticipated to be Ready by the End of May 2024 SAN CARLOS, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -

  • Zacks

    Why Iovance (IOVA) Might Surprise This Earnings Season

    Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.